Perkins Capital Management’s Matinas BioPharma MTNB Stock Holding History

Perkins Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-290	Closed	-$19K	–	112
2021 Q3	$19K	Buy	+290	New	+$12.5K	0.01%	105

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Perkins Capital Management's MTNB Position: Q4 2021 in Review

Perkins Capital Management sold out of Matinas BioPharma (MTNB) in Q4 2021, closing a stake of 290 shares — an estimated $19K sold.

Perkins Capital Management first reported a position in MTNB in Q3 2021 and held it in 1 quarter. The position peaked at $19K in Q3 2021. 66 funds tracked by Wall St. Rank hold MTNB as of Q4 2021.

Perkins Capital Management reported no remaining Matinas BioPharma position as of Q4 2021 after selling out during the quarter.
Perkins Capital Management sold 290 Matinas BioPharma shares in Q4 2021, an estimated $19K.
Perkins Capital Management first reported a position in Matinas BioPharma in Q3 2021 and held it in 1 quarter.
Perkins Capital Management's Matinas BioPharma position peaked at $19K in Q3 2021.
66 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2021.

Based on Perkins Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.